One particular type of BRAF mutation, called BRAF V600E, is present in around 5% to 10% of patients with metastatic colorectal cancer. Historically, metastatic colorectal cancer driven by a BRAF ...

as well as an increase in overall survival (OS), when used as a first-line treatment for colorectal cancer with BRAF V600E mutations. Both results were "clinically meaningful," according to a ...

Two months after rejecting Pierre Fabre’s Braftovi for a rare form of metastatic colorectal cancer ... people diagnosed with bowel cancer who have a BRAF V600E mutation are currently extremely ...

Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has ... the combination in mCRC patients living with a BRAF ...

BRAF V600E mutations are common in different tumor types (more frequently in melanomas, colon and thyroid carcinomas). BRAF Alterations in Brain Tumors: Different Diagnostic Relevance of BRAF ...

Caris Life Sciences has collected $168 million in new funding to support the growth of its precision medicine platforms, ...

In combination with trametinib for the treatment of pediatric patients with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. Not for treatment of colorectal cancer ...

Biomarkers, precision medicine, early detection to revolutionize CRC care in India: Dr. Sumant Gupta: Shardul Nautiyal, ...